Back to top

3 Stocks Under $10 That Surged Today

Read MoreHide Full Article

Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on earnings estimate revisions in order to find winning stocks. However, we also always seek to cover stocks, big and small, that are making noteworthy moves.

Furthermore, we understand that stocks with low prices can often catch many investors’ eyes. One group of stocks that investors sometimes pay particular attention to are those currently trading under $10 per share. These stocks present retail investors with the opportunity to take a considerable position in a company.

The ability to buy up large positions—akin to intuitional investors that grab large chunks of S&P 500 giants—also means that stocks trading for $10 or less are often subject to massive one-day swings.

Now, let’s take a look at three companies trading for less than $10 per share that surged today:

Ramaco Resources, Inc. (METC - Free Report)

This coal company saw its stock price surge by nearly 8% on Thursday. Before today’s climb, shares of Ramaco had popped over 45% within the last four weeks. Based on our current Zacks Consensus Estimates, Ramaco’s earnings are projected to soar in its current full-year as it looks set to re-enter the black. This EPS growth is also expected to continue into the following fiscal year. Ramaco is currently a Zacks Rank #2 (Buy).

Novavax, Inc. (NVAX - Free Report)

Shares of Novavax popped over 4.65% today, bringing the stock to around $1.81 per share. Novavax is currently working on a vaccine for the respiratory syncytial virus, which reportedly sends more infants to American emergency rooms than any other virus. Within the last four weeks, shares of Novavax have skyrocketed nearly 55%, as investors hope to get in on the ground floor of a potentially game-changing drug. This small-cap, clinical-stage biotech firm is currently a Zacks Rank #3 (Hold).

Fate Therapeutics, Inc. (FATE - Free Report)

Shares of this clinical-stage biopharmaceutical firm, which specializes in cellular immunotherapies for cancer and immune disorders, popped 3.16% today. Before today’s climb, Fate Therapeutics stock had soared nearly 75% over the last 12 weeks, lifting the stock near its 52-week high. Like many other clinical-stage biotech companies, Fate is still in the red. However, the company’s revenues are expected to surge 39% in 2018 as it tries to inch closer to the black. Fate is currently a Zacks Rank #3 (Hold).

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Novavax, Inc. (NVAX) - free report >>

Fate Therapeutics, Inc. (FATE) - free report >>

ROMACO RESOURCS (METC) - free report >>

More from Zacks Stocks in the News

You May Like